



Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

February 6, 2025

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025, prior to the open of U.S. markets.

The Company's management will also host a conference call and webcast at 8:30 am ET on Wednesday, February 19, 2025, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: <https://www.webcaster4.com/Webcast/Page/3018/51976>.

For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company's website at www.krystalbio.com.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).

CONTACT

Investors and Media:

Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com



Source: Krystal Biotech, Inc.